Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

about

Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.

Item

http://www.wikidata.org/entity/Q52677126

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Dasatinib in Pediatric Patient ...... Results From a Phase II Trial.

@en

Dasatinib in Pediatric Patient ...... Results From a Phase II Trial.

@nl

type

Item

label

Dasatinib in Pediatric Patient ...... Results From a Phase II Trial.

@en

Dasatinib in Pediatric Patient ...... Results From a Phase II Trial.

@nl

prefLabel

Dasatinib in Pediatric Patient ...... Results From a Phase II Trial.

@en

Dasatinib in Pediatric Patient ...... Results From a Phase II Trial.

@nl

P1476

Dasatinib in Pediatric Patient ...... Results From a Phase II Trial.

@en

P2093

Andrew E Place

http://www.w3.org/2001/XMLSchema#string

C Michel Zwaan

http://www.w3.org/2001/XMLSchema#string

Carmino Antonio De Souza

http://www.w3.org/2001/XMLSchema#string

Donna Lancaster

http://www.w3.org/2001/XMLSchema#string

Franca Fagioli

http://www.w3.org/2001/XMLSchema#string

Jong Jin Seo

http://www.w3.org/2001/XMLSchema#string

Judith Landman-Parker

http://www.w3.org/2001/XMLSchema#string

Karen R Rabin

http://www.w3.org/2001/XMLSchema#string

Lee

http://www.w3.org/2001/XMLSchema#string

Lia Gore

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.

Targeting developmental pathways in children with cancer: what price success?

Pediatric chronic myeloid leukemia is a unique disease that requires a different approach

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.

Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.

P304

1330-1338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2017.75.9597

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29498925

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

chronic myeloid leukemia

P932

5929218

http://www.w3.org/2001/XMLSchema#string